NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.34 -0.17 (-1.26 %)
(As of 01/22/2019 04:00 PM ET)
Previous Close$13.51
Today's Range$13.16 - $13.93
52-Week Range$8.10 - $19.58
Volume4,800 shs
Average Volume40,914 shs
Market Capitalization$423.12 million
P/E Ratio-1.68
Dividend YieldN/A
Beta-0.58
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.47 per share

Profitability

Net Income$-115,450,000.00

Miscellaneous

Employees30
Market Cap$423.12 million
OptionableNot Optionable

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04. View Clementia Pharmaceuticals' Earnings History.

When is Clementia Pharmaceuticals' next earnings date?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Clementia Pharmaceuticals.

What price target have analysts set for CMTA?

5 equities research analysts have issued twelve-month price targets for Clementia Pharmaceuticals' shares. Their predictions range from $16.00 to $26.00. On average, they expect Clementia Pharmaceuticals' stock price to reach $23.00 in the next year. This suggests a possible upside of 72.4% from the stock's current price. View Analyst Price Targets for Clementia Pharmaceuticals.

What is the consensus analysts' recommendation for Clementia Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clementia Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clementia Pharmaceuticals.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Media coverage about CMTA stock has been trending very positive on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clementia Pharmaceuticals earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 52)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 62)
  • Mr. Jeffery Packman, Chief Devel. Officer (Age 52)
  • Mr. Steve Forte, CFO & Corp. Sec.
  • Mr. Joseph Andrew Walewicz, Exec. VP of Bus. & Corp. Devel. (Age 50)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

Who are Clementia Pharmaceuticals' major shareholders?

Clementia Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (8.54%).

Which institutional investors are buying Clementia Pharmaceuticals stock?

CMTA stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC.

How do I buy shares of Clementia Pharmaceuticals?

Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $13.34.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $423.12 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

What is Clementia Pharmaceuticals' official website?

The official website for Clementia Pharmaceuticals is http://www.clementiapharma.com.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (NASDAQ CMTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel